𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma

✍ Scribed by Ahmad A. Tarhini; Michael Millward; Paul Mainwaring; Richard Kefford; Ted Logan; Anna Pavlick; Steven J. Kathman; Kevin H. Laubscher; Mohammed M. Dar; John M. Kirkwood

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
140 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 clinical trial of nab-paclitax
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
✍ Evan M. Hersh; Steven J. O'Day; Antoni Ribas; Wolfram E. Samlowski; Michael S. G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

## Abstract ## BACKGROUND: __nab__‐Paclitaxel (ABI‐007, Abraxane), a 130‐nM, albumin‐bound (__nab__) particle form of Cremophor‐free paclitaxel, is approved for metastatic breast cancer. In the current study, the efficacy and safety of __nab__‐paclitaxel were evaluated in previously treated and ch

A Phase II study of “decrescendo” interl
A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy
✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

Randomized trial of treatment with cispl
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma : A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study
✍ Thierry Dorval; Sylvie Négrier; Christine Chevreau; Marie-Françoise Avril; Danie 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## Background: The objective of the current study was to evaluate the response rate, survival, and toxicity of treatment with cisplatin and high dose intravenous continuous infusion interleukin-2 (il-2) with or without interferon-alpha-2a (ifn) in patients with metastatic melanoma. ## Methods: On